Anemia and outcomes in patients with type 2 diabetes mellitus and nephropathy: lessons from the RENAAL trialToto, R D
The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) study was conducted from 1996 to 2001. This landmark clinical trial provided the opportunity to study renal and cardiovascular outcomes, as well as risk predictors, in a relatively large number of patients ...
Renaal Study-update RENAAL使用AIIA氯沙坦改变伴2型糖尿病和肾病的高血压患者的肾病进程 血管紧张素II主导高血压的病理学进程 血管功能紊乱 内皮功能紊乱重构/增生纤维化动脉粥样硬化 心脏组织功能紊乱 细胞丢失纤维化重构缺血 心梗，心衰终末期肾病中风 肾脏脑 高血压 基因,危险因素(糖尿病、高脂血症)，环境(饮食、...
Data from the Angiotensin II Antagonist Losartan Study (RENAAL) and Irbesartan type II Diabetic Nephropathy Trial (IDNT) were used. The kidney outcome was time to first event of end-stage kidney disease or doubling of serum creatinine. The cardiovascular outcome was time to first event of a co...
Observational analysis of IDNT (Irbesartan Diabetic Nephropathy Trial) and the RENAAL (Reduction of End Points in NonInsulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study. 2,739 participants with type 2 diabetes and nephropathy with at least 1 year of blood pressure ...
A Japanese subpopulation analysis of the Reduction of Endpoints in non-insulin-dependent diabetes mellitus (NIDDM) with the Angiotensin II Antagonist Losartan (RENAAL), the landmark trial, has been published in this issue of Clinical and Experimental Nephrology, the official journal of the Japanese ...
Methods: The Reduction of Endpoints in \\{NIDDM\\} with the Angiotensin \\{II\\} Receptor Antagonist Losartan (RENAAL) study was a randomized, double-blind, multinational, clinical trial that studied 1,513 patients with type 2 diabetes and nephropathy for a mean of 3.4 years. Patients were...
Patients with type 2 diabetes and advanced renal disease were enrolled in a trial comparing losartan (Cozaar), 50鈥 100 mg once daily, with placebo, both taken in addition to conventional antihypertensive treatment (calcium-channel antagonists, diuretics, 伪-blockers, 尾-...
METHODS: The data from the RENAAL (Reduction in End Points in Noninsulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan) study, a double-blind, randomized trial, were used to examine the effects of losartan on the renal outcome [i.e., the primary composite end point ...
This landmark clinical trial provided the opportunity to study renal and cardiovascular outcomes, as well as risk predictors, in a relatively large number of patients with Type 2 diabetes and nephropathy. The RENAAL study also provided information that will be valuable to those designing future ...